85 related articles for article (PubMed ID: 9717818)
41. Phase II clinical trial of a murine monoclonal antibody cytotoxic for gastrointestinal adenocarcinoma.
Sears HF; Herlyn D; Steplewski Z; Koprowski H
Cancer Res; 1985 Nov; 45(11 Pt 2):5910-3. PubMed ID: 4053061
[TBL] [Abstract][Full Text] [Related]
42. Immunotherapy of human colon cancer by antibody-targeted superantigens.
Dohlsten M; Lando PA; Björk P; Abrahmsén L; Ohlsson L; Lind P; Kalland T
Cancer Immunol Immunother; 1995 Sep; 41(3):162-8. PubMed ID: 7553685
[TBL] [Abstract][Full Text] [Related]
43. Effects of monoclonal antibody immunotherapy on patients with gastrointestinal adenocarcinoma.
Sears HF; Herlyn D; Steplewski Z; Koprowski H
J Biol Response Mod; 1984; 3(2):138-50. PubMed ID: 6374043
[TBL] [Abstract][Full Text] [Related]
44. Phase I study of SS1P, a recombinant anti-mesothelin immunotoxin given as a bolus I.V. infusion to patients with mesothelin-expressing mesothelioma, ovarian, and pancreatic cancers.
Hassan R; Bullock S; Premkumar A; Kreitman RJ; Kindler H; Willingham MC; Pastan I
Clin Cancer Res; 2007 Sep; 13(17):5144-9. PubMed ID: 17785569
[TBL] [Abstract][Full Text] [Related]
45. Phase II study of anguidine in gastrointestinal malignancies: a Southwest Oncology Group study.
Bukowski R; Vaughn C; Bottomley R; Chen T
Cancer Treat Rep; 1982 Feb; 66(2):381-3. PubMed ID: 7055820
[TBL] [Abstract][Full Text] [Related]
46. Effects of a superantigen-antibody recombinant fusion protein (r-C242 Fab-SEA) on toxicological responses in the anaesthetised rabbit.
Ilbäck NG; Gunnarsson K; Persson R; Lindh U; Stålhandske T
Toxicology; 2003 Mar; 185(1-2):161-74. PubMed ID: 12505454
[TBL] [Abstract][Full Text] [Related]
47. Phase I clinical trial of MAF containing preparation of RPMI-1788 B-cell human lymphoblastoid lymphokine in advanced cancer patients.
Reynolds RD; Khojasteh A; Papermaster BW; McEntire JE
Lymphokine Res; 1986; 5 Suppl 1():S165-70. PubMed ID: 3537547
[TBL] [Abstract][Full Text] [Related]
48. TAK-264 (MLN0264) in Previously Treated Asian Patients with Advanced Gastrointestinal Carcinoma Expressing Guanylyl Cyclase C: Results from an Open-Label, Non-randomized Phase 1 Study.
Bang YJ; Takano T; Lin CC; Fasanmade A; Yang H; Danaee H; Asato T; Kalebic T; Wang H; Doi T
Cancer Res Treat; 2018 Apr; 50(2):398-404. PubMed ID: 28494535
[TBL] [Abstract][Full Text] [Related]
49. A phase I, first-in-human study of TAK-164, an antibody-drug conjugate, in patients with advanced gastrointestinal cancers expressing guanylyl cyclase C.
Kim R; Leal AD; Parikh A; Ryan DP; Wang S; Bahamon B; Gupta N; Moss A; Pye J; Miao H; Inguilizian H; Cleary JM
Cancer Chemother Pharmacol; 2023 Apr; 91(4):291-300. PubMed ID: 36738333
[TBL] [Abstract][Full Text] [Related]
50. Phase I trial of homoharringtonine.
Neidhart JA; Young DC; Derocher D; Metz EN
Cancer Treat Rep; 1983 Sep; 67(9):801-4. PubMed ID: 6883357
[TBL] [Abstract][Full Text] [Related]
51. Phase I study in malignancy of LS 2616, a new immunomodulator: methodological considerations.
Nilsson BI
Cancer Detect Prev; 1988; 12(1-6):553-9. PubMed ID: 3180145
[TBL] [Abstract][Full Text] [Related]
52. Clinical study of recombinant DNA-produced leukocyte interferon (clone A) in a intermittent schedule in cancer patients.
Quesada JR; Gutterman JU
J Natl Cancer Inst; 1983 Jun; 70(6):1041-6. PubMed ID: 6190033
[TBL] [Abstract][Full Text] [Related]
53. Phase I clinical trial of drug-monoclonal antibody conjugates in patients with advanced colorectal carcinoma: a preliminary report.
Tjandra JJ; Pietersz GA; Teh JG; Cuthbertson AM; Sullivan JR; Penfold C; McKenzie IF; Smyth M
Surgery; 1989 Sep; 106(3):533-45. PubMed ID: 2788931
[TBL] [Abstract][Full Text] [Related]
54. A wide-spectrum paired comparison of the properties of the Rolling 6 and 3+3 Phase I study designs.
Sposto R; Groshen S
Contemp Clin Trials; 2011 Sep; 32(5):694-703. PubMed ID: 21554993
[TBL] [Abstract][Full Text] [Related]
55. Defining dose-limiting toxicity for phase 1 trials of molecularly targeted agents: results of a DLT-TARGETT international survey.
Paoletti X; Le Tourneau C; Verweij J; Siu LL; Seymour L; Postel-Vinay S; Collette L; Rizzo E; Ivy P; Olmos D; Massard C; Lacombe D; Kaye SB; Soria JC
Eur J Cancer; 2014 Aug; 50(12):2050-6. PubMed ID: 24928189
[TBL] [Abstract][Full Text] [Related]
56. Initial observations on the administration of thymus extract (TFX) in patients with alimentary tract neoplasms.
Cybulski L; Turowski G; Politowski M; Urban A; Turaszwili T; Zubel M
Pol Med Sci Hist Bull (1973); 1976; 15(1):47-9. PubMed ID: 995755
[TBL] [Abstract][Full Text] [Related]
57. Staphylococcal enterotoxins as good candidates for cancer immunotherapy: a systematic review.
Shivaee A; Sedighi M; Imani Fooladi AA
Ann Ig; 2020; 32(6):648-663. PubMed ID: 33175076
[TBL] [Abstract][Full Text] [Related]
58. A phase 2a clinical study on the safety and efficacy of individualized dosed mebendazole in patients with advanced gastrointestinal cancer.
Mansoori S; Fryknäs M; Alvfors C; Loskog A; Larsson R; Nygren P
Sci Rep; 2021 Apr; 11(1):8981. PubMed ID: 33903692
[TBL] [Abstract][Full Text] [Related]
59. Phase I Clinical Trials in Patients ≥80.
Gaddipati H; Fu P; Dowlati A
J Geriatr Oncol; 2011 Apr; 2(2):142-146. PubMed ID: 21603079
[TBL] [Abstract][Full Text] [Related]
60. Immune Targeting in Gastrointestinal Malignancies: Finding the Right Combination for the Right Site.
Manji GA
Oncology (Williston Park); 2016 Jan; 30(1):91-3. PubMed ID: 26791850
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
